{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:27:05Z","timestamp":1768264025820,"version":"3.49.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Scientific Research from the Japanese Breast Cancer Society"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s12282-018-0896-y","type":"journal-article","created":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T07:07:36Z","timestamp":1532675256000},"page":"106-112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results"],"prefix":"10.1007","volume":"26","author":[{"name":"Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Nakatsukasa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimi","family":"Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisako","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimito","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mana","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhisa","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Shigematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Taira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Narui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshie","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daishu","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,27]]},"reference":[{"key":"896_CR1","first-page":"13","volume":"5307459","author":"J Wang","year":"2018","unstructured":"Wang J, Lv H, Xue Z, Wang L, Bai Z, et al. Temporal trends of common female malignances on breast, cervical, and ovarian cancer mortality in Japan, Republic of Korea, and Singapore: application of the age-period-cohort model. Biomed Res Int. 2018;5307459:13","journal-title":"Biomed Res Int."},{"key":"896_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.6004\/jnccn.2016.0181","volume":"14","author":"W Gradishar","year":"2016","unstructured":"Gradishar W, Salerno KE. NCCN guidelines update: breast cancer. J Natl Compr Canc Netw. 2016;14:641\u20134.","journal-title":"J Natl Compr Canc Netw"},{"key":"896_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","volume":"69","author":"P Hadji","year":"2009","unstructured":"Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2009;69:73\u201382.","journal-title":"Crit Rev Oncol Hematol"},{"key":"896_CR4","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00223-015-0046-x","volume":"97","author":"SJ Lee","year":"2015","unstructured":"Lee SJ, Kim KM, Brown JK, Brett A, Roh YH, Kang DR, et al. Negative impact of aromatase inhibitors on proximal femoral bone mass and geometry in postmenopausal women with breast cancer. Calcif Tissue Int. 2015;97:551\u20139.","journal-title":"Calcif Tissue Int"},{"key":"896_CR5","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3803\/EnM.2015.30.1.58","volume":"30","author":"W Kim","year":"2015","unstructured":"Kim W, Chung Y, Kim SH, Park S, Bae JH, Kim G, et al. Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. Endocrinol Metab (Seoul). 2015;30:58\u201364.","journal-title":"Endocrinol Metab (Seoul)"},{"key":"896_CR6","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/annonc\/mdn762","volume":"20","author":"P Hadji","year":"2009","unstructured":"Hadji P, Ziller M, Kieback DG, Dornoff W, Tessen HW, Menschik T, et al. Effects of exemestane and tamoxifen on bone health within the tamoxifen exemestane adjuvant multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy. Ann Oncol. 2009;20:1203\u20139.","journal-title":"Ann Oncol"},{"key":"896_CR7","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s00432-014-1726-z","volume":"140","author":"I Kyvernitakis","year":"2014","unstructured":"Kyvernitakis I, Rachner TD, Urbschat A, Hars O, Hofbauer LC, Hadji P. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer. J Cancer Res Clin Oncol. 2014;140:1671\u201380.","journal-title":"J Cancer Res Clin Oncol"},{"key":"896_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00432-013-1557-3","volume":"140","author":"I Kyvernitakis","year":"2014","unstructured":"Kyvernitakis I, Knoll D, Struck M, Hars O, Bauer T, Hadji P. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole. J Cancer Res Clin Oncol. 2014;140:159\u201366.","journal-title":"J Cancer Res Clin Oncol"},{"key":"896_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0140-6736(05)67036-5","volume":"366","author":"A Howell","year":"2015","unstructured":"Howell A. Adjuvant aromatase inhibitors for breast cancer. Lancet. 2015;366:431\u201333.","journal-title":"Lancet"},{"key":"896_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","volume":"8","author":"RE Coleman","year":"2007","unstructured":"Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup exemestane study (IES): a randomised controlled study. Lancet Oncol. 2007;8:119\u201327.","journal-title":"Lancet Oncol"},{"key":"896_CR11","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005;97:1262\u201371.","journal-title":"J Natl Cancer Inst"},{"key":"896_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1200\/JCO.2006.08.8617","volume":"25","author":"AS Coates","year":"2007","unstructured":"Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1\u201398. J Clin Oncol. 2007;25:486\u201392.","journal-title":"J Clin Oncol"},{"key":"896_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-018-0917-0","author":"K Nakatsukasa","year":"2018","unstructured":"Nakatsukasa K, Koyama J, Ouchi Y, Sakaguchi K, Fujita Y, Matsuda T, et al. Effects of denosumab on bone mineral density in Japanese women with osteoporosis treated with aromatase inhibitors for breast cancer. J Bone Miner Metab. 2018. https:\/\/doi.org\/10.1007\/s00774-018-0917-0 .","journal-title":"J Bone Miner Metab."},{"key":"896_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesez R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet. 2015;386:433\u201343.","journal-title":"Lancet"},{"key":"896_CR15","doi-asserted-by":"publisher","first-page":"104","DOI":"10.7326\/0003-4819-157-2-201207170-00466","volume":"157","author":"HD Nelson","year":"2012","unstructured":"Nelson HD, Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the US preventive services task force recommendations. Ann Intern Med. 2012;157:104\u201313.","journal-title":"Ann Intern Med"},{"key":"896_CR16","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1056\/NEJM199410203311604","volume":"331","author":"EP Smith","year":"1994","unstructured":"Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med. 1994;331:1056\u201361.","journal-title":"N Engl J Med"},{"key":"896_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S8756-3282(01)00643-3","volume":"30","author":"NA Sims","year":"2002","unstructured":"Sims NA, Dupont S, Krust A, Clement-Lacroix P, Minet D, Resche-Rigon M, et al. Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-beta in bone remodeling in females but not in males. Bone. 2002;30:18\u201325.","journal-title":"Bone"},{"key":"896_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1096\/fj.08-113456","volume":"23","author":"F Callewaert","year":"2009","unstructured":"Callewaert F, Venken K, Ophoff J, De Gendt K, Torcasio A, van Lenthe GH, et al. Differential regulation of bone and body composition in male mice with combined inactivation of androgen and estrogen receptor-alpha. FASEB J. 2009;23:232\u201340.","journal-title":"FASEB J"},{"key":"896_CR19","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jbmr.209","volume":"26","author":"J Ford","year":"2011","unstructured":"Ford J, Hajibeigi A, Long M, Hahner L, Gore C, Hsieh JT, et al. GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. J Bone Miner Res. 2011;26:298\u2013307.","journal-title":"J Bone Miner Res"},{"key":"896_CR20","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1083\/jcb.145.3.527","volume":"145","author":"TL Burgess","year":"1999","unstructured":"Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol. 1999;145:527\u201338.","journal-title":"J Cell Biol"},{"key":"896_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","volume":"93","author":"DL Lacey","year":"1998","unstructured":"Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165\u201376.","journal-title":"Cell"},{"key":"896_CR22","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","volume":"95","author":"H Yasuda","year":"1998","unstructured":"Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci USA. 1998;95:3597\u2013602.","journal-title":"Proc Natl Acad Sci USA"},{"key":"896_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2013.11.016","volume":"59","author":"RM Zebaze","year":"2014","unstructured":"Zebaze RM, Libanati C, Austin M, Ghasem-Zadeh A, Hanley DA, Zanchetta JR, et al. Differing effects of denosumab and alendronate on cortical and trabecular bone. Bone. 2014;59:173\u201379.","journal-title":"Bone"},{"key":"896_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2012;27:243\u201354.","journal-title":"J Bone Miner Res"},{"key":"896_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"896_CR26","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8:1137\u201348.","journal-title":"J Bone Miner Res"},{"key":"896_CR27","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1002\/jbmr.149","volume":"25","author":"IR Reid","year":"2010","unstructured":"Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010;25:2256\u201365.","journal-title":"J Bone Miner Res"},{"key":"896_CR28","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1002\/jbmr.2236","volume":"29","author":"JP Brown","year":"2014","unstructured":"Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen LE, et al. Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. J Bone Miner Res. 2014;29:2051\u201356.","journal-title":"J Bone Miner Res"},{"key":"896_CR29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3233\/XST-150481","volume":"23","author":"F Montagner","year":"2015","unstructured":"Montagner F, Kaftandjian V, Farlay D, Brau D, Boivin G, Follet H. Validation of a novel microradiography device for characterization of bone mineralization. J X-ray Sci Technol. 2015;23:201\u201311.","journal-title":"J X-ray Sci Technol"},{"key":"896_CR30","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/sim.3870","volume":"29","author":"E Vittinghoff","year":"2010","unstructured":"Vittinghoff E, McCulloch CE, Woo C, Cummings SR. Estimating long-term effects of treatment from placebo-controlled trials with an extension period, using virtual twins. Stat Med. 2010;29:1127\u201336.","journal-title":"Stat Med"},{"key":"896_CR31","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s12282-016-0746-8","volume":"24","author":"S Ota","year":"2017","unstructured":"Ota S, Inoue R, Shiozaki T, Yamamoto Y, Hashimoto N, Takeda O, et al. Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis. Breast Cancer. 2017;24:601\u20137.","journal-title":"Breast Cancer"},{"key":"896_CR32","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bonr.2017.02.006","volume":"6","author":"M Shabestari","year":"2017","unstructured":"Shabestari M, Eriksenb EF, Paschalis EP, Roschger P, Gamsjaeger S, Klaushofer K, et al. Presence of pyrophosphate in bone from an atypical femoral fracture site: a case report. Bone Rep. 2017;6:81\u20136.","journal-title":"Bone Rep"},{"key":"896_CR33","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","volume":"35","author":"T Yoneda","year":"2017","unstructured":"Japanese Allied Committee on Osteonecrosis of the Jaw. Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, et al. Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. J Bone Miner Metab 2017;35:6\u201319.","journal-title":"J Bone Miner Metab"},{"key":"896_CR34","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s00198-015-3458-6","volume":"27","author":"AW Popp","year":"2016","unstructured":"Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016;27:1917\u201321.","journal-title":"Osteoporos Int"},{"key":"896_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/jc.2017-00096","volume":"102","author":"O Lamy","year":"2017","unstructured":"Lamy O, Gonzalez-Rodriguez E, Stoll D, Hans D, Aubry-Rozier B. Severe rebound-associated vertebral fractures after denosumab discontinuation: 9 clinical cases report. J Clin Endocrinol Metab. 2017;102:354\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"896_CR36","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM Trial and its extension. J Bone Miner Res. 2018;33:190\u20138.","journal-title":"J Bone Miner Res"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-018-0896-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-0896-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-018-0896-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T21:01:39Z","timestamp":1604696499000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-018-0896-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,27]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["896"],"URL":"https:\/\/doi.org\/10.1007\/s12282-018-0896-y","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,27]]},"assertion":[{"value":"18 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr Tetsuya Taguchi received Research grant from Chugai, Taiho and Daiichi Sankyo. Dr Shunji Takahashi received Research grant from Daiichi Sankyo. Other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standard.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}